

# Oral Presentations at 2026 ASCO Annual Meeting



Note: all times listed are Central Time

## PRESENTATION

## SPEAKER

## SESSION/TIME

### Friday, May 29, 2026

**1519** LLM-generated serious illness conversation summaries to improve care for hospitalized patients: A pilot clinical trial

Chris Manz, MD,  
MPH

**Rapid Oral Abstract Session**  
Care Delivery; Models of Care  
Hall D1 | 2:45pm-4:15pm CT

**LBA7506** Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomab and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SuCCESSOR-2 trial

Paul Richardson, MD

**Oral Abstract Session**  
Hematologic Malignancies;  
Plasma Cell Dyscrasia  
S100a | 2:45pm-5:45pm CT

**4502** ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial

Toni Choueiri, MD

**Oral Abstract Session**  
Genitourinary Cancer: Kidney and Bladder  
Arie Crown Theater | 2:45 PM-5:45 PM CT

### Saturday, May 30, 2026

**10015** Phase II trial of olaparib and ceralasertib in patients with recurrent osteosarcoma: Lung-only resectable cohort efficacy and correlative biomarker results

Suzanne J. Forrest,  
MD (DFBC)

**Rapid Oral Abstract Session**  
Pediatric Oncology II  
S504 | 8:00am-9:30am CT

**8519** Safety and efficacy results of phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations

Julia Rotow, MD

**Rapid Oral Abstract Session**  
Lung Cancer: Non-Small Cell Metastatic  
Hall D2 | 1:15pm-2:45pm CT

**11500** Primary results of the phase 3 study of bezuclastinib + sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST)

Andrew Wagner, MD,  
PhD

**Oral Abstract Session**  
Sarcoma  
S100bc | 3:00pm-6:00pm CT

**5004** A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101)

Atish Choudhury,  
MD, PhD

**Oral Abstract Session**  
Genitourinary Cancer:  
Prostate, Testicular, and Penile  
Hall D1 | 3:00pm-6:00pm CT

# Oral Presentations at 2026 ASCO Annual Meeting



Note: all times listed are Central Time

## PRESENTATION

## SPEAKER

## SESSION/TIME

### Saturday, May 30, 2026 (continued)

**5005** Cognitive effects of darolutamide vs enzalutamide – results of ARACOG (AFT-47) a randomized clinical trial from the alliance for clinical trials in oncology

Alicia Morgans, MD,  
MPD

**Oral Abstract Session**  
Genitourinary Cancer:  
Prostate, Testicular, and Penile  
Hall D1 | 3:00pm-6:00pm CT

**2006** A personalized neoantigen vaccine to reprogram the immune landscape of glioblastoma

David Reardon, MD

**Oral Abstract Session**  
Central Nervous System Tumors  
S100a | 3:00pm-6:00pm CT

### Sunday, May 31, 2026

**12010** Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial

Jennifer Ligibel, MD

**Rapid Oral Abstract Session**  
Symptom Science and Palliative Care  
S403 | 8:00am-9:30am CT

**11003** Overall survival analysis of eSyM: A cluster randomized trial of an electronic patient-reported outcomes (ePRO)-based symptom management program

Michael Hassett, MD,  
MPH

**Oral Abstract Session**  
Quality Care, Health Services Research  
S100bc | 8:00am-11:00am CT

**2506** Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H-mutated unresectable advanced solid tumors

Rishi Surana, MD,  
PhD

**Oral Abstract Session**  
Developmental Therapeutics:  
Immunotherapy  
Arie Crown Theater | 8:00am-11:00am CT

**1013** ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC)

Sara Tolaney, MD,  
MPH

**Rapid Oral Abstract Session**  
Breast Cancer: Metastatic  
Hall D1/11:30am-1:00pm CT

# Oral Presentations at 2026 ASCO Annual Meeting



Note: all times listed are Central Time

## PRESENTATION

## SPEAKER

## SESSION/TIME

### Sunday, May 31, 2026 (continued)

**LBA1** Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study

Mary-Ellen Taplin, MD

**Plenary Session**  
Hall B1 | 1:00pm-4:00pm CT

**LBA5** Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study

Brian Wolpin, MD,  
MPH

**Plenary Session**  
Hall B1 | 1:00pm-4:00pm CT

### Monday, June 1, 2026

**6010** Emiltatug ledadotin (Emi-Le), a B7-H4-directed antibody-drug conjugate (ADC), in patients with aggressive adenoid cystic carcinoma (ACC): Phase 1 interim analysis

Glenn Hanna, MD

**Clinical Science Symposium**  
Small Glands, Big Challenges: Novel Therapeutics in Salivary Gland Cancer  
E450b | 8:00am-9:30am CT

### Tuesday, June 2, 2026

**LBA1000** Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro

Sara Tolaney, MD,  
MPH (Senior author)

**Oral Abstract Session**  
Breast Cancer: Metastatic  
Hall HD1 | 9:45am-12:45pm CT